SUBSCRIBE
SUBSCRIBE

Acrivon Therapeutics

NEWS
Deals
Acrivon Becomes Biotech’s 20th IPO of 2022 with $99M Offering
Acrivon Therapeutics announced the pricing of its initial public offering Tuesday, putting all of its 7,550,000 shares of common stock up for sale for $12.50 apiece.
November 15, 2022
 · 
1 min read
 · 
Tristan Manalac
John Maraganore/ courtesy Lane Turner/The Boston G
Business
BioSpace Movers & Shakers: John Maraganore, Larry Alstiel, Brad Margus and More
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
April 21, 2022
 · 
7 min read
 · 
Alex Keown
JOBS
IN THE PRESS
Business
Acrivon Therapeutics Announces the Appointment of Adam Levy, Ph.D., M.B.A., Experienced Biotech Investor Relations and Strategy Executive, to Senior Vice President and Head, Investor Relations and Corporate Affairs
July 25, 2023
 · 
5 min read
Business
Acrivon Therapeutics Announces the Appointment of Seasoned Biopharma Executive Charles Baum, M.D., Ph.D., a Recognized Leader in Clinical Precision Oncology, to its Board of Directors
June 23, 2023
 · 
5 min read
Business
Akoya Biosciences to Partner with Acrivon Therapeutics for the Clinical Development of Acrivon’s Proprietary OncoSignature® Test into a Companion Diagnostic
June 28, 2022
 · 
6 min read